Clinical trial
Safety, Tolerability, and the Body's Ability to Develop Resistance to an…
NCT00109122 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00109122 |
|---|---|
| Title | Safety, Tolerability, and the Body's Ability to Develop Resistance to an Investigational Vaccine for Shingles (V211-007) |
| Official title | A Double-Blind, Placebo-Controled, Randomized Study to Evaluate Safety, Tolerability, and Immunogenicity After 1 and 2 Doses of Zoster Vaccine |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Shingles |
| Intervention type | Biological |
| Interventions | zoster vaccine live (Oka/Merck), Comparator: placebo (unspecified) |
| Enrollment | 180 |
| Start date | Nov 1, 2001 |
| Primary completion | Feb 1, 2003 |
| Completion | Jul 1, 2006 |
| First posted | Apr 25, 2005 |
| Last update posted | Mar 15, 2017 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: